The Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetes Pipeline Report:
Companies across the globe are diligently working toward developing novel Diabetes treatment therapies with a considerable amount of success over the years.
Diabetes companies working in the treatment market are Carmot Therapeutics, Amytrx Therapeutics, Sciwind Biosciences, Novo Nordisk, Novartis, Regor Pharmaceuticals, ILTOO Pharma, Novartis, Eli Lilly and Company, and others, are developing therapies for the Diabetes treatment
Emerging Diabetes therapies in the different phases of clinical trials are- CT996, AMTX 100, XW014, NNC0471-0119, MHS552, RGT001-075, ILT-101, Iscalimab, LY-3209590, Insulin icodec, and others are expected to have a significant impact on the Diabetes market in the coming years.
In August 2023, By the end of 2023, VTv Therapeutics intends to start a Phase III clinical study for cadisegliatin as a treatment for type 1 diabetes (T1D), after which it will apply to the US Food and Drug Administration (FDA) for marketing authorization.
In September 2023, Over the next three years, Novo Nordisk will work with Harvard and the Massachusetts Institute of Technology’s Broad Institute to create three new programmes to combat diabetes and heart fibrosis.
In May 2021, Novo Nordisk began a 26-week study to evaluate the efficacy and safety of once-weekly insulin icodec and once-daily insulin glargine 100 units/mL in patients with type 2 diabetes on a basal-bolus regimen when combined with bolus insulin and non-insulin anti-diabetic drugs.
Diabetes mellitus (DM) is derived from the Latin word mellitus, which means sweet, and the Greek word diabetes, which means syphon – to pass through. It is a chronic illness that impairs the body’s capacity to regulate blood sugar levels and utilise food as fuel. Carbohydrates from food are converted in a healthy body to glucose, which then powers the cells.
Get a Free Sample PDF Report to know more about Diabetes Pipeline Therapeutic Assessment-
Emerging Diabetes Drugs Under Different Phases of Clinical Development Include:
CT996: Carmot Therapeutics
AMTX 100: Amytrx Therapeutics
XW014: Sciwind Biosciences
NNC0471-0119: Novo Nordisk
RGT001-075: Regor Pharmaceuticals
ILT-101: ILTOO Pharma
LY-3209590: Eli Lilly and Company
Insulin icodec: Novo Nordisk
Diabetes Route of Administration
Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Diabetes Molecule Type
Diabetes Products have been categorized under various Molecule types, such as
Diabetes Pipeline Therapeutics Assessment
Diabetes Assessment by Product Type
Diabetes By Stage and Product Type
Diabetes Assessment by Route of Administration
Diabetes By Stage and Route of Administration
Diabetes Assessment by Molecule Type
Diabetes by Stage and Molecule Type
DelveInsight’s Diabetes Report covers around 200+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Diabetes product details are provided in the report. Download the Diabetes pipeline report to learn more about the emerging Diabetes therapies
Some of the key companies in the Diabetes Therapeutics Market include:
Key companies developing therapies for Diabetes are – Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and others
Diabetes Pipeline Analysis:
The Diabetes pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment.
Diabetes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetes drugs and therapies
Diabetes Pipeline Market Drivers
Increasing Prevalence, government bodies are collaborating with major market players for the launch of new products, increase in the demand for insulin over the world, growing geriatric population, which is susceptible to type-1 diabetes are some of the important factors that are fueling the Diabetes Market.
Diabetes Pipeline Market Barriers
However, side-effects associated with the treatment of Diabetes, a lack of knowledge about a healthy diet, medication initiation, lack of awareness among patients regarding types of treatment available and other factors are creating obstacles in the Diabetes Market growth.
Scope of Diabetes Pipeline Drug Insight
Key Diabetes Companies: Carmot Therapeutics, Amytrx Therapeutics, Sciwind Biosciences, Novo Nordisk, Novartis, Regor Pharmaceuticals, ILTOO Pharma, Novartis, Eli Lilly and Company, and others
Key Diabetes Therapies: CT996, AMTX 100, XW014, NNC0471-0119, MHS552, RGT001-075, ILT-101, Iscalimab, LY-3209590, Insulin icodec, and others
Diabetes Therapeutic Assessment: Diabetes current marketed and Diabetes emerging therapies
Diabetes Market Dynamics: Diabetes market drivers and Diabetes market barriers
Request for Sample PDF Report for Diabetes Pipeline Assessment and clinical trials
Table of Contents
1. Diabetes Report Introduction
2. Diabetes Executive Summary
3. Diabetes Overview
4. Diabetes- Analytical Perspective In-depth Commercial Assessment
5. Diabetes Pipeline Therapeutics
6. Diabetes Late Stage Products (Phase II/III)
7. Diabetes Mid Stage Products (Phase II)
8. Diabetes Early Stage Products (Phase I)
9. Diabetes Preclinical Stage Products
10. Diabetes Therapeutics Assessment
11. Diabetes Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetes Key Companies
14. Diabetes Key Products
15. Diabetes Unmet Needs
16 . Diabetes Market Drivers and Barriers
17. Diabetes Future Perspectives and Conclusion
18. Diabetes Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States